Stuart obtained his PhD at La Trobe University, and subsequently undertook research positions at Wageningen University, The Netherlands, and then the University of New South Wales. He moved to Adelaide in 1998 and began his current research interests in examining cell signalling pathways controlled by sphingolipids, and how they contribute to cancer, viral infections, wound healing and other conditions. His research has primarily focused on the molecular mechanisms governing the sphingosine kinases, the pivotal enzymes controlling sphingolipid metabolism, determining how these are altered in disease, and approaches to target these to improve human health. His laboratory has made a number of important contributions to the field, including... Read more
About me
Stuart obtained his PhD at La Trobe University, and subsequently undertook research positions at Wageningen University, The Netherlands, and then the University of New South Wales. He moved to Adelaide in 1998 and began his current research interests in examining cell signalling pathways controlled by sphingolipids, and how they contribute to cancer, viral infections, wound healing and other conditions. His research has primarily focused on the molecular mechanisms governing the sphingosine kinases, the pivotal enzymes controlling sphingolipid metabolism, determining how these are altered in disease, and approaches to target these to improve human health. His laboratory has made a number of important contributions to the field, including the cloning of the first human sphingosine kinase, and identification of key phosphorylations and protein interactions relating to the sphingosine kinases that have (patho)physiological significance, as well as the development of novel inhibitors with potential clinical application.
Research
Excludes commercial-in-confidence projects.
Targeting sphingolipid metabolism in disease, NHMRC - Senior Principal Research Fellowship, 01/01/2019 - 31/12/2023
Targeting sphingosine kinase 1 to sensitise acute myeloid leukaemia to BH3 mimetic therapy, NHMRC - Project Grant, 01/01/2018 - 31/12/2020
Modulating sphingolipid signalling to enhance wound healing, NHMRC - Project Grant, 01/01/2017 - 31/12/2019
Central Adelaide Local Health Network Incorporated Scholarship, Central Adelaide Local Health Network Incorporated, 01/01/2016 - 31/05/2019
Defining the mechanisms regulating tissue mechano-reciprocity in wound healing, NHMRC - Project Grant, 01/01/2016 - 31/12/2018
Sphingosine kinase as a target for anti-cancer therapy, NHMRC - Research Fellowship, 01/01/2014 - 31/12/2018
Cancer Discovery Accelerator, Australian Cancer Research Foundation, 01/06/2016 - 31/07/2018
Central Adelaide Local Health Network Incorporated Scholarship, Central Adelaide Local Health Network Incorporated, 01/01/2016 - 31/03/2018
Defining the role of a palmitoylated variant of sphingosine kinase 1 in cancer, NHMRC - Project Grant, 01/01/2015 - 31/12/2017
Targeting sphingosine kinases to improve glioblastoma therapy, Neurosurgical Research Foundation, 21/06/2016 - 30/09/2017
Targeting Sphingosine Kinase 1C Degradation to Enhance Chemosensitivity', Central Adelaide Local Health Network Incorporated, 01/01/2016 - 30/06/2017
Cancer Discovery Accelerator, Cancer Council SA - Beat Cancer, 08/06/2016 - 08/06/2017
Liquid handling robot and cell analysis systems, Neurosurgical Research Foundation, 17/10/2016 - 30/05/2017
Enhancing wound healing via modulation of the sphingosine kinase/ sphingosine 1-phosphate pathway, Royal Adelaide Hospital, 12/02/2015 - 28/02/2016
Targeting sphingosine kinase 1c degradation to enhance cancer chemotherapeutic sensitivity, Cancer Council SA - Beat Cancer, 01/01/2015 - 31/12/2015
Roles and regulations of sphingosine kinase 1 during dengue virus infection, NHMRC - Project Grant, 01/01/2014 - 31/12/2015
A new target for allergic inflammation: the sphingolipid pathway, NHMRC - Project Grant, 01/01/2014 - 31/12/2015
Targetting the CIB1-sphingosine kinase interaction in oncogenesis, NHMRC - Project Grant, 01/01/2014 - 30/04/2015
Characterising a highly oncogenic variant of sphingosine kinase 1, Cancer Council SA - Beat Cancer, 01/01/2014 - 31/12/2014
Research
Research since 2008 is shown below. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2018 |
1
|
2013 |
1
2
|
Year | Output |
---|---|
2018 |
|
2018 |
Open access
|
2018 |
Open access
1
|
2018 |
4
4
5
|
2018 |
1
|
2018 |
Open access
1
1
3
|
2017 |
Open access
1
1
1
|
2017 |
Open access
2
1
|
2017 |
7
6
62
|
2017 |
13
12
85
|
2017 |
Open access
1
2
6
|
2017 |
Open access
4
3
1
|
2017 |
Open access
7
8
8
|
2017 |
9
7
|
2017 |
Open access
8
6
2
|
2016 |
11
12
|
2016 |
Open access
11
11
1
|
2016 |
Open access
4
4
|
2016 |
Open access
31
26
|
2016 |
Open access
2
|
2016 |
Open access
12
9
|
2016 |
Open access
24
25
|
2016 |
Open access
16
14
1
|
2016 |
9
7
1
|
2016 |
10
7
1
|
2015 |
Open access
7
4
2
|
2015 |
Open access
16
14
|
2015 |
Open access
1
|
2015 |
13
12
1
|
2015 |
Open access
8
7
1
|
2015 |
Open access
29
28
3
|
2015 |
Open access
13
9
26
|
2015 |
Open access
23
20
1
|
2015 |
Open access
25
20
|
2015 |
Open access
14
10
|
2014 |
Open access
38
39
1
|
2014 |
Open access
3
|
2014 |
7
12
|
2014 |
Open access
35
30
1
|
2014 |
Open access
74
67
25
|
2013 |
16
16
|
2013 |
22
21
|
2013 |
19
20
|
2013 |
Open access
79
75
4
|
2013 |
Open access
14
12
4
|
2012 |
Open access
60
60
3
|
2012 |
Open access
31
29
1
|
2012 |
72
66
6
|
2012 |
25
25
2
|
2012 |
42
42
|
2012 |
25
|
2012 |
15
15
|
2011 |
8
9
|
2011 |
20
17
|
2011 |
17
|
2011 |
38
30
|
2011 |
33
36
|
2011 |
20
17
|
2011 |
178
162
|
2011 |
14
14
|
2011 |
21
16
6
|
2011 |
30
33
|
2010 |
83
|
2010 |
41
39
1
|
2010 |
76
70
3
|
2010 |
55
|
2010 |
54
53
|
2010 |
32
30
|
2010 |
21
19
|
2010 |
24
|
2010 |
Open access
118
108
3
|
2010 |
43
|
2010 |
46
43
|
2009 |
29
26
|
2009 |
14
11
|
2009 |
17
|
2009 |
7
7
|
2009 |
28
|
2009 |
42
33
|
2009 |
Open access
14
10
|
2009 |
19
17
|
2008 |
40
32
|
2008 |
40
37
3
|
2008 |
66
|
2008 |
15
|
2008 |
|
Research
Details | Registry | Status |
---|---|---|
Modulators of 14-3-3 functionality and uses thereof Woodcock, Joanna; Lopez, Angel; Pitson, Stuart; Samuel, Michael; Coolen, Carl |
WO | Filed |
External engagement & recognition
Organisation | Country |
---|---|
Australian National University | AUSTRALIA |
Babraham Institute | UNITED KINGDOM |
Baker Heart and Diabetes Institute | AUSTRALIA |
Central Adelaide Local Health Network Incorporated | AUSTRALIA |
Central Queensland University | AUSTRALIA |
Charité - Universitätsmedizin Berlin | GERMANY |
City University of New York | UNITED STATES |
Columbia University | UNITED STATES |
Cornell University | UNITED STATES |
CSIRO Australia (Commonwealth Scientific Industrial Research Organisation) | AUSTRALIA |
Flinders University | AUSTRALIA |
Garvan Medical Institute | AUSTRALIA |
Griffith University | AUSTRALIA |
Hanson Centre for Cancer Research | AUSTRALIA |
Hanson Institute | AUSTRALIA |
Imperial College of Science, Technology and Medicine | UNITED KINGDOM |
Institute of Medical and Veterinary Science | AUSTRALIA |
Jilin University | CHINA |
Kanazawa University | JAPAN |
La Trobe University | AUSTRALIA |
Medical University of Innsbruck | AUSTRIA |
Medical University of South Carolina | UNITED STATES |
Monash University | AUSTRALIA |
National Institutes of Health | UNITED STATES |
New York University | UNITED STATES |
QIMR Berghofer Medical Research Institute | AUSTRALIA |
Queen Elizabeth Hospital | AUSTRALIA |
Royal Adelaide Hospital | AUSTRALIA |
SA Pathology | AUSTRALIA |
Shanghai University | CHINA |
South Australian Health and Medical Research Institute (SAHMRI) | AUSTRALIA |
St. Vincent's Institute of Medical Research | AUSTRALIA |
Stanford University | UNITED STATES |
The Alfred Hospital | AUSTRALIA |
The Kinghorn Cancer Centre | AUSTRALIA |
University of Adelaide | AUSTRALIA |
University of Auckland | NEW ZEALAND |
University of Chicago | UNITED STATES |
University of Connecticut | UNITED STATES |
University of Essen | GERMANY |
University of Illinois at Chicago | UNITED STATES |
University of Kent | UNITED KINGDOM |
University of Louisville | UNITED STATES |
University of Melbourne | AUSTRALIA |
University of New South Wales | AUSTRALIA |
University of North Carolina at Chapel Hill | UNITED STATES |
University of Queensland | AUSTRALIA |
University of South Australia | AUSTRALIA |
University of Strathclyde | UNITED KINGDOM |
University of Sydney | AUSTRALIA |
University of Tennessee | UNITED STATES |
University of Texas | UNITED STATES |
University of Toronto | CANADA |
University of Toulouse - Jean Jaures | FRANCE |
University of Toulouse Iii Paul Sabatier | FRANCE |
University of Zurich | SWITZERLAND |
Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
Washington University | UNITED STATES |
Westmead Hospital | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
NHMRC Senior Research FellowInstitute of Medical and Veterinary Science (IMVS) |
2017 |
NHMRC Senior Research FellowInstitute of Medical and Veterinary Science (IMVS) |
2016 |
Project GrantNational Health and Medical Research Council (NHMRC) |
2016 |
NHMRC Senior Research FellowInstitute of Medical and Veterinary Science (IMVS) |
2015 |
NHMRC Senior Research FellowInstitute of Medical and Veterinary Science (IMVS) |
2014 |
NHMRC Senior Research FellowInstitute of Medical and Veterinary Science (IMVS) |
2013 |
NHMRC Senior Research FellowInstitute of Medical and Veterinary Science (IMVS) |
2012 |
NHMRC Senior Research FellowInstitute of Medical and Veterinary Science (IMVS) |
2011 |
NHMRC Senior Research FellowInstitute of Medical and Veterinary Science (IMVS) |
2010 |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
Investigating rho-rock signalling pathway contribution to mammary tumorigenesis | Current |
Targeting multiple myeloma by manipulation of sphingolipid metabolism | Current |
Targeting sphingosine kinase 1 (SK1) in acute myeloid leukaemia (AML) | Current |
Understanding the role of 14-3-3 proteins in lung cancer initiation, progression and metastasis. | Current |
Peroxisome proliferator-activated receptor gamma interacts with sphingosine 1-phosphate to regulate vascular function | Completed |